Dr John Low Seng Hooi

• SL Morris, SH Low, RP A’ Hern, TG Eisen, ME Gore, CM Nutting, KJ Harrington. A prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic malignant melanoma. British Journal of Cancer 2004; 91:829-833.
• J.S.H. Low, D.M.K.Heng, J.T.S. Wee. The Question of T2a and N3a in the UICC/AJCC (1997) staging system for nasopharyngeal carcinoma. Clinical Oncology (R Coll Radiol) 2004; 16(8): 581- 583.
• John SH Low, Eu-Tiong Chua, Joseph..TS Wee. Stereotactic Radiosurgery (SRS) plus Intracavitary Irradiation (ICI) in the salvage of rT1 and rT2 persistent and recurrent Nasopharyngeal Carcinoma (NPC), Lung Cancer 2004, 46(S1): S50.
• J SH Low, EH Wong, HS KhooTan, SP Yap, VJ Sethi, EJ Chua, J Low, EH Tay, LT Soh. Adjuvant Sequential Chemotherapy and Radiotherapy in Uterine Papillary Serous Carcinoma. Gynecologic Oncology 2005; 97(1): 171-177.
• John S.H Low, Fei Gao, Ta Wen Yu, Jeffrey Tuan, Ivan Tham, Hoon Seng Khoo Tan, Tong Hong Khor. Curative Radiotherapy in Elderly patients with cervix cancer – do they fare worse compared to their younger counterparts? Int J Rad Oncol Bio Phys 2005, 63(2S1): S347.
• John SH Low, Eu Tiong Chua, Fei Gao, Joseph TS Wee. Stereotactic Radiosurgery plus Intracavitary Irradiation in the salvage of Nasopharyngeal Carcinoma (NPC). Head Neck 2006; 28(4): 321-329.
• J SH Low, KB Ng. Modified Fletcher’s 3 Channel Brachytherapy System with Vaginal Line Source Loading versus Uterine Tandem & Vaginal Cylinder System in Stage IIIA Cervical Cancer. Biomed Imaging and Interv J 2006; 2(1): e15.
• L Wong, HT See, HS KhooTan, JS Low, WT Ng, JJ Low. Combined adjuvant cisplatin and ifosfamide chemotherapy and radiotherapy for malignant mixed mullerian tumors of the uterus. Int J Gynecol Cancer 2006; 16(3): 1364-9.
• J SH Low, WY Koh, SP Yap, KW Fong. Radical Radiotherapy in stage I Non-Small Cell Lung Cancer (NSCLC) – Singapore National Cancer Centre Experience. Ann Acad Med Singapore 2007; 36(9):778-83.
• Chua ML, Ong SC, Wee JT, Ng DC, Gao F, Tan TW, Fong KW, Chua ET, Khoo JB, Low JS. Comparison of 4 modalities in distant metastatic staging in endemic nasopharyngeal carcinoma. Head Neck.2009; 31(3):346-54.
• Puan KJ, Low JS, Tan TW, Wee JT, Tan EH, Fong KW, Chua ET, Jin C, Giner JL, Morita CT, Goh CH, Hui KM. Phenotypic and functional alterations of carcinoma. Cancer Immunology, Immunotherapy 2009; 58(7):1095-1107.
• SP Heng, S Kandaiya, John low Seng Hooi. The influence of the bowel and bladder preparation protocol for radiotherapy of prostate cancer using kilo-voltage cone beam CT. Indian Journal of Cancer 2013.
• SP Heng, SH Low, S Kandaiya. Increased in dose to organ at risks did not correlate with the weight loss but did correlate with the lateral neck dimension reduction and volume changes for head and neck patients treated with intensity-modulated radiotherapy. Head Neck Oncol 2014 May 03;6(1):9.
• L.I. Tan, S.H. Low, N. Mat-Nor, S.P. Heng. Quality of Life in Nasopharyngeal Cancer (NPC) Patients: Study of Salivary Flow Recovery Pattern on Xerostomia Improvement for Intensity Modulated Radiation Therapy (IMRT) Versus Volumetric Modulated Arc Therapy (VMAT). Int J Rad Oncol Bio Phys 2014, 90(1S): S525:2795.
• Norfadilah Mat Nor, R. Ahmad, Heng Siew Peng, L.S.H. John et al. Immobilisation precision in VMAT for oral cancer patients. Journal of Physics Conference Series May 2017; 851(1): 012025.
• Ho GF, Chai CS, Alip A, Wahid MI, Abdullah MM, Foo YC, How SH, Zaatar A, Lam KS, Leong KW, Low JS. Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study. BMC cancer. 2019 Dec;19(1):1-1.
• Md Yusof M, Abdullah MM, Yap BK, Ng SC, Low JS, Lam KS, Ahmad Badruddin RB, Lai CN, Lau KL, Chong KJ, Nonis JG. Real‐world multicenter study of the safety and efficacy of netupitant plus palonosetron fixed‐dose combination to prevent chemotherapy‐induced nausea and vomiting among Malaysian patients receiving moderately or highly emetogenic chemotherapy. Asia‐Pacific Journal of Clinical Oncology. 2021 Nov 23.
• Gao QL, Zhu J, Zhao W, Huang Y, An R, Zheng H, Qu P, Wang L, Zhou Q, Wang D, Lou G, Wang J, Low J. L-MOCA: An open-label study of olaparib maintenance monotherapy in platinumsensitive relapsed ovarian cancer. Journal of Clinical Oncology 2021; 39, no. 15_suppl.
• Gao, Q., Zhu, J., Zhao, W., Huang, Y., An, R., Zheng, H., Qu P, Wang L, Zhou Q, Wang D, Lou G, Wang J, Wang K, Low J. & Ma, D. Olaparib maintenance monotherapy in Asian patients with platinum-sensitive relapsed ovarian cancer: Phase III trial (L-MOCA). Clinical Cancer Research 2022, 28(11), 2278-2285.
• Wu L, Li J, Xu C, Biswas B, Tang K, Wang H, Liu Z, Batra U, Ho GF, Low SH, Lu Y. 1337P Real-world utilization and outcomes of dacomitinib as first-line positive NSCLC: An interim analysis of the ARIA study. Annals of Oncology. 2023 Oct 1;34:S771.

• Singapore Medical Council (SMC) – full registration (1997 – present)
• Malaysia Medical Council (MMC) – full registration (2005 – present)
• Singapore Society of Oncology
• South-East Asian Radiation Oncology Group (SEAROG)
• American Society of Clinical Oncology (ASCO)
• American Society for Radiation Oncology (ASTRO)
• Malaysian Oncological Society (Life member)

Nasopharyngeal Cancer

• A Multicentre, Randomized, Open-Label, Phase III Clinical Trial of Gemcitabine and Carboplatin followed by Epstein Barr Virus-Specific Autologous T Lymphocytes versus Gemcitabine and Carboplatin as First Line Treatment for Advanced Nasopharyngeal Carcinoma Patients. (Tessa Therapeutic Sponsored International Multicentre Trial) Role: Principal Investigator
• Randomised Trial of RT vs CCRT followed by Adjuvant Chemotherapy in AJCC/ UICC Stage III/ IV Nasopharyngeal Carcinoma of the Endemic Variety
  Role: Co-Investigator
  Presentation: ASCO Annual Meeting 2004
  Publication: J Clin Oncol 2005; 23:6730-6738
• Development of A Gamma-delta T Cells Therapeutic Regimen for Human Nasopharyngeal Carcinoma. (BMRC grant – Investigator Initiated Trial)
  Role: Principal Investigator
  Presentation: Singapore General Hospital Scientist Award 25 April 2008
  Publication: Cancer Immunology, Immunotherapy 2009; 58:1095-1107
• A Randomized Phase II Study to Investigate the Effects of Recombinant Intestinal Trefoil Factor (ITF) on Oral Mucositis in Patients Receiving Radiation Therapy for Nasopharyngeal Cancer. (GI Company Sponsored Trial) Role: Co-Investigator
• CT-PET vs Conventional Staging in Nasopharyngeal Carcinoma. (SingHealth Research Grant)
  Role: Principal Investigator
  Presentation: ASTRO Annual Meeting 2007
  Publication: Head Neck 2009; 31:346-54
• Randomized Phase II Triplet Chemotherapy Regime (Gemcitabine/ Cisplatin/ Paclitaxel) followed Concurrent Cisplatin-RT in Nasopharyngeal Carcinoma. (BMRC Research Grant) Role: Co-Investigator
• Modified Suppressive Subtractive Hybridization (MSSH) & Real-time PCR Analysis of sera in Nasopharyngeal cancer patients pre-post radical radiotherapy (Molecular Research Unit, NCC Singapore)
  Role: Principal Investigator
  Breast Cancer
• A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician’s Choice for Metastatic Triple Negative Breast Cancer (mTNBC). (MSD Sponsored International Multicentre Trial)
  Role: Co-Investigator
• An Open-Label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribocliclib (LEE11) in Combination with Letrozole for the Treatment of Men and Postmenopausal Women with Hormone Receptor-Positive (HR+), HER2-Negative (HER2-) Advanced Breast Cancer (ABC) with No Prior Hormonal Therapy for Advanced Disease. (Novartis Sponsored International Multicentre Trial)
  Role: Co-Investigator
• A Randomized, 3 Arm, Multicentre, Phase III Study to Evaluate the Efficacy and the Safety of TDM1 Combined with Pertuzumab or T-DM1 Combined with Pertuzumab-Placebo (Blinded for Pertuzumab), versus the Combination of Trastuzumab plus Taxane, as First Line Treatment in
  HER2- Positive Progressive or Recurrent Locally Advanced or Metastatic Breast Cancer (MBC). (Roche Sponsored International Multicentre Trial)
  Role: Principal Investigator
• Prospective Observational Study of Mobile App-Based Patient-Reported Outcomes in Advanced Brest Cancer in Asia (Pfizer Sponsored International Multicentre Trial)
  Role: Co-Investigator
• An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribocliclib (LEE11) in Combination with Letrozole for the Treatment of Men and Postmenopausal Women with Hormone Receptor-Positive (HR+), HER2-negative (HER2-) Advanced Breast Cancer (ABC) with No Prior Hormonal Therapy for Advanced Disease (Novartis Sponsored International Multicentre Trial)
  Role: Co-Investigator
• A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (KEYNOTE-355) (MSD Sponsored International Multicentre Trial)
  Role: Co-Investigator
• A Phase III Double-Blind Randomisation Study Accessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-Line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (CAPitello-290) (AstraZeneca Sponsored International Multicentre Trial)
  Role: Co-Investigator
• A Two-part, Phase III, Multicenter, Randomized (1:1), Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination with Trastuzumab and Pertuzumab as Maintenance Therapy in Patients with HER2-Positive Advanced Breast Cancer with a PIK3CA Mutation (EPIK-B2) (Novartis Sponsored International Multicentre Trial)
  Role: Co-Investigator
• A Phase III, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination with Nab-Paclitaxel in Patients with Advanced Triple Negative Breast Cancer with either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss without PIK3CA Mutation (EPIK-B3) (Novartis Sponsored International Multicentre Trial)
  Role: Co-Investigator
• A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (SERENA-4) (AstraZeneca Sponsored International Multicentre Trial)
  Role: Principal Investigator
• A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Metastatic Breast Cancer (MI3475-B49) (MSD Sponsored International Multicentre Trial)
  Role: Co-Investigator
  Lung Cancer
• A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer (Celltrion Sponsored International Multicentre Trial)
  Role: Co-Investigator
• A Multiple Center, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of Erlotinib (Tarceva®) versus Gemcitabine/ Cisplatin as the First-Line Treatment for Stage IIIB/ IV Non-Small Cell Lung Cancer (NSCLC) Patients with Mutations in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor (EGFR) in Their Tumors. (Roche Sponsored International Multicentre Trial)
  Role: Principal Investigator
• A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1. (MSD Sponsored International Multicentre Trial)
  Role: Co-Investigator
• A Multi-Country, Multi-Centre, Observational, Retrospective Study to Reveal the Patient Characteristics, Disease Burden, Treatment Patterns and Patient Journey of Stage III Non-SmallCell Lung Cancer Patients (AstraZeneca Sponsored International Multicentre Trial)
  Role: Co-Investigator
• A Two-Part Randomized, Phase 3 Study of Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer. (Regeneron Sponsored International Multicentre Trial)
  Role: Co-Investigator
• A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer (Celltrion Sponsored International Multicentre Trial)
  Role: Co-Investigator
• A Phase II Single-Arm Study to Investigate Tepotinib Combined with Osimertinib in MET Amplified, Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior 1st to 3rd Generation EGFR-Tyrosine Kinase Inhibitor Therapy (INSIGHT-2) (Merck KGaA Sponsored International Multicentre Trial)
  Role: Co-Investigator
• A Phase 3 Study to Evaluate Zimberelimab (AB122) Combined with AB154 in Front-Line, PD-L1-High, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (ARC-10) (Arcus Bioscience Sponsored International Multicentre Trial)
  Role: Principal Investigator
• Real-World Utilization and Outcomes with Dacomitinib First-Line Treatment for EGFR MutationPositive Advanced Non-Small Cell Lung Cancer among Asian Patients – A Multi-Center Chart Review
  Role: Principal Investigator
• A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy (PACIFIC-8) (AstraZeneca Sponsored International Multicentre Trial)
  Role: Principal Investigator
• A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery System in Patients with EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy (PALOMA-3) (Janssen Sponsored International Multicentre Trial)
  Role: Principal Investigator
• A Phase III, Double blind, Randomised, Placebo Controlled, International Study to assess the Efficacy and Safety of Adjuvant Osimertinib versus Placebo in Participants with EGFR mutation positive Stage IA2 IA3 Non- small Cell Lung Cancer, following Complete Tumour Resection (ADAURA-2) (AstraZeneca Sponsored International Multicentre Trial)
  Role: Co-Investigator
  Cervical Cancer
• Prospective Phase II Study of Neoadjuvant Docetaxel-Cisplatin Chemotherapy followed by Concurrent Chemotherapy in Locally Advanced Cervical Cancer. (Sanofi-Aventis Sponsored Trial – Investigator Initiated Trial)
  Role: Principal Investigator
  Head and Neck Cancer
• Phase III Randomised Trial of Concomitant Radiation, Cisplatin, and Tirapazamine (SR259075) versus Concomitant Radiation and Cisplatin in Patients with Advanced Head and Neck Cancer. (Sanofi-Aventis Sponsored Trial)
  Role: Co-Investigator
  Publication: J Clin Oncol 2008; 28: 2989 – 2995
• Phase III, Double-Blinded, Placebo-Controlled Study of Post-Operative Adjuvant Concurrent Chemo-Radiotherapy with or without Nimotuzumab for Stage III/ IV Head and Neck Squamous Cell Cancer. (Innogene Sponsored International Trial)
  Role: Principal Investigator
  Liver Cancer
• A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) versus Placebo and BSC as Second-Line Treatment in Patients with Hepatocellular Carcinoma following First-Line Therapy with Sorafenib. (ImClone/ Eli Lilly Sponsored International Multicentre Trial)
  Role: Principal Investigator
• A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination with Tremelimumab ± Lenvatinib Given Concurrently with Transarterial Chemoembolization (TACE) Compared to TACE Alone in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-3) (AstraZeneca Sponsored International Multicentre Trial)
  Role: Principal Investigator
  Colorectal Cancer
• Aspirin for Dukes C and High-Risk Dukes B Colorectal Cancers – An International, Multi-Centre, Double-Blind Randomised Placebo-Controlled Phase III Trial. (Singapore Clinical Research Institute Sponsored trial)
  Role: Principal Investigator
• A Phase 3 study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK3475]) Versus Standard of Care in Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (KEYFORM-007) (MSD Sponsored International Multicentre Trial)
  Role: Co-Investigator
  Stomach Cancer
• A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (Astella Sponsored International Multicentre Trial)
  Role: Co-Investigator
  Ovarian Cancer
• An Open Label, Single Aram, Multicentre Study to Assess the Clinical Efficacy and Safety of Lynparza (Olaparib) Tablets Maintenance Monotherapy in Platinum Sensitive Relapsed Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy (L-MOCA) (AstraZeneca Sponsored International Multicentre Trial)
  Role: Principal Investigator
  Biliary Tract Cancer
• A Phase 3 Randomized, Double-Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/ or Unresectable Biliary Tract Carcinoma (KEYNOTE-966) (MSD Sponsored International Multicentre Trial)
  Role: Principal Investigator
  Thyroid Cancer
• A Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Dabrafenib plus Trametinib in Previously Treated Patients with Locally Advanced or Metastatic, Radio-Active Iodine Refractory BRAFV600E Mutation-Positive Differentiated Thyroid Cancer (Novartis Sponsored International Multicentre Trial)
  Role: Principal Investigator